ReviewPharmacoEconomics2011
Health technology funding decision-making processes around the world: the same, yet different.
Review in PharmacoEconomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- A systematic review of moral reasons on orphan drug reimbursement.Orphanet journal of rare diseases · 2021Pooled it
- Pooled it
- Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.PharmacoEconomics · 2018Pooled it
- A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.Healthcare policy = Politiques de sante · 2015Pooled it
- Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?The patient · 2015Pooled it
- A systematic review of stated preference studies reporting public preferences for healthcare priority setting.The patient · 2014Pooled it
- Does moral reasoning influence public values for health care priority setting?: A population-based randomized stated preference survey.Health policy (Amsterdam, Netherlands) · 2020Trial
- What should be publicly funded in the Colombian health system? A mixed methods study of citizens' perceptions.BMJ open · 2025Article
- Topic identification, selection, and prioritization for health technology assessment in selected countries: a mixed study design.Cost effectiveness and resource allocation : C/E · 2024Article
- Development of the WHO-INTEGRATE evidence-to-decision framework: an overview of systematic reviews of decision criteria for health decision-making.Cost effectiveness and resource allocation : C/E · 2020Review
- Protocol for an Economic Evaluation of the Quitlink Randomized Controlled Trial for Accessible Smoking Cessation Support for People With Severe Mental Illness.Frontiers in psychiatry · 2019Article
- Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments.International journal of environmental research and public health · 2018Article
- Protocol for an economic evaluation of WHO STOPS childhood obesity stepped-wedge cluster randomised controlled trial.BMJ open · 2018Article
- Nature and reporting characteristics of UK health technology assessment systematic reviews.BMC medical research methodology · 2018Article
- How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.PharmacoEconomics · 2017Article
- Public drug policy for children in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Review
- Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies.Frontiers in pharmacology · 2017Article
- BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles.PharmacoEconomics · 2016Review
- Mapping capacity to conduct health technology assessment in Central, Eastern and South-Eastern Europe.Croatian medical journal · 2016Article
- Evaluating the quality and use of economic data in decisions about essential medicines.Bulletin of the World Health Organization · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
All healthcare systems routinely make resource allocation decisions that trade off potential health gains to different patient populations. However, when such trade-offs relate to the introduction of new, promising health technologies, perceived 'winners' and 'losers' are more apparent. In recent years, public scrutiny over such decisions has intensified, raising the need to better understand how they are currently made and how they might be improved. The objective of this paper is to critically review and compare current processes for making health technology funding decisions at the regional, state/provincial and national level in 20 countries. A comprehensive search for published, peer-reviewed and grey literature describing actual national, state/provincial and regional/institutional technology decision-making processes was conducted. Information was extracted by two independent reviewers and tabulated to facilitate qualitative comparative analyses. To identify strengths and weaknesses of processes identified, websites of corresponding organizations were searched for commissioned reviews/evaluations, which were subsequently analysed using standard qualitative methods. A total of 21 national, four provincial/state and six regional/institutional-level processes were found. Although information on each one varied, they could be grouped into four sequential categories: (i) identification of the decision problem; (ii) information inputs; (iii) elements of the decision-making process; and (iv) public accountability and decision implementation. While information requirements of all processes appeared substantial and decision-making factors comprehensive, the way in which they were utilized was often unclear, as were approaches used to incorporate social values or equity arguments into decisions. A comprehensive inventory of approaches to implementing the four main components of all technology funding decision-making processes was compiled, from which areas for future work or research aimed at improving the acceptability of decisions were identified. They include the explication of decision criteria and social values underpinning processes.
Indexed as
Identifiers
21568357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.